Study with Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure with Severely Reduced Ejection Fraction

Recruiting

Phase 3

Study with Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure with Severely Reduced Ejection FractionStudy with Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure with Severely Reduced Ejection Fraction

Sponsor:

Cytokinetics

Code:

NCT06736574

Conditions

Heart Failure

Heart Failure with Reduced Ejection Fraction

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Omecamtiv Mecarbil (OM)

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Cytokinetics on 2025-03-25.